NorthWest Biotherapeutics Inc (NWBO)

[Ready4bluesky]

Yes, but there have been many warnings about this trial using PFS vs. OS for the primary end point and complicated further by the unusable secondary endpoint (because of confounding issues). All valid concerns which were quickly dismissed by the majority of this board.

At least this trial will be a useful reminder for future companies/trials that the gold standard has been and continues to be OS for trial design. Also an important lesson for investors new to biotech (like myself) how one little flaw in trial design can jeopardize the whole mission. Actually jeopardize the entire company for those with a limited pipeline.

I feel like everything is slowly coming into focus and for that I am grateful. Not the result I was hoping for, but final resolution will make it possible to move on to other opportunities.